Sitagliptin intolerance.
Kargili
A
A
Karakurt
F
F
Kankilic
M Nur
MN
Kankilic
E S
ES
Bozkurtl
B
B
D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D003937:Diagnosis, Differential; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015994:Incidence; D008875:Middle Aged; D015508:Nasal Obstruction; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects*; D012135:Respiratory Sounds; D012220:Rhinitis / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects*; D014421:Turkey
D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate